IL219132A0 - Benzazepine compound - Google Patents

Benzazepine compound

Info

Publication number
IL219132A0
IL219132A0 IL219132A IL21913212A IL219132A0 IL 219132 A0 IL219132 A0 IL 219132A0 IL 219132 A IL219132 A IL 219132A IL 21913212 A IL21913212 A IL 21913212A IL 219132 A0 IL219132 A0 IL 219132A0
Authority
IL
Israel
Prior art keywords
benzazepine compound
benzazepine
compound
Prior art date
Application number
IL219132A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of IL219132A0 publication Critical patent/IL219132A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Studio Devices (AREA)
IL219132A 2009-10-26 2012-04-15 Benzazepine compound IL219132A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009245434 2009-10-26
PCT/JP2010/068807 WO2011052519A1 (ja) 2009-10-26 2010-10-25 ベンズアゼピン化合物

Publications (1)

Publication Number Publication Date
IL219132A0 true IL219132A0 (en) 2012-06-28

Family

ID=43921941

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219132A IL219132A0 (en) 2009-10-26 2012-04-15 Benzazepine compound

Country Status (17)

Country Link
US (1) US8940727B2 (enExample)
EP (1) EP2495236A4 (enExample)
JP (1) JP5717645B2 (enExample)
KR (1) KR20120092139A (enExample)
CN (3) CN102753530B (enExample)
AU (1) AU2010312651A1 (enExample)
BR (1) BR112012009784A2 (enExample)
CA (1) CA2778756A1 (enExample)
CO (1) CO6481003A2 (enExample)
EA (1) EA022253B1 (enExample)
IL (1) IL219132A0 (enExample)
IN (1) IN2012DN03343A (enExample)
MX (1) MX2012004843A (enExample)
PH (1) PH12012500762A1 (enExample)
SG (1) SG10201406839VA (enExample)
WO (1) WO2011052519A1 (enExample)
ZA (1) ZA201202640B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2019003433A1 (ja) * 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
JP6868089B2 (ja) * 2018-12-28 2021-05-12 大塚製薬株式会社 医薬
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
CN121449554B (zh) * 2026-01-07 2026-04-28 浙江大学医学院附属邵逸夫医院(浙江省邵逸夫医院) 一种包含具有2-芳甲酰基苯并氮杂䓬结构的小分子化合物的药物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
UA64690C2 (en) * 1993-07-21 2004-03-15 Yamanouty Farmaceutical Co Ltd A condensed benzadepine derivative, an intermediate compound for preparing thereof and a pharmaceutical composition
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
CA2654445A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
WO2008049116A2 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
WO2009117144A1 (en) * 2008-03-20 2009-09-24 Concert Pharmaceuticals, Inc. Benzazepine compounds

Also Published As

Publication number Publication date
US8940727B2 (en) 2015-01-27
JP5717645B2 (ja) 2015-05-13
CO6481003A2 (es) 2012-07-16
CN102753530B (zh) 2015-06-17
CN102753530A (zh) 2012-10-24
JPWO2011052519A1 (ja) 2013-03-21
CN104447555A (zh) 2015-03-25
CN104829531A (zh) 2015-08-12
US20130131045A1 (en) 2013-05-23
CA2778756A1 (en) 2011-05-05
ZA201202640B (en) 2013-06-26
EA022253B1 (ru) 2015-11-30
WO2011052519A1 (ja) 2011-05-05
SG10201406839VA (en) 2014-12-30
EP2495236A1 (en) 2012-09-05
EP2495236A4 (en) 2013-03-27
BR112012009784A2 (pt) 2016-05-17
PH12012500762A1 (en) 2012-11-26
KR20120092139A (ko) 2012-08-20
IN2012DN03343A (enExample) 2015-10-23
EA201290228A1 (ru) 2012-12-28
AU2010312651A1 (en) 2012-05-03
MX2012004843A (es) 2012-05-29

Similar Documents

Publication Publication Date Title
HUS1700026I1 (hu) Tetraciklusos vegyület
GB0907425D0 (en) Compounds
EP2393493A4 (en) LINKS
GB0903759D0 (en) Compound
EP2423182A4 (en) DIACYLETHYLENDIAMINVERBINDUNG
GB0907515D0 (en) Compounds
GB0804989D0 (en) Compound
GB0914767D0 (en) Compound
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
ZA201202640B (en) Benzazepine compound
GB0909213D0 (en) Compound
EP2487178A4 (en) PYRAZOLOTHIAZOLVERBINDUNG
LT2546255T (lt) Benzazepino junginys
GB0909672D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0914883D0 (en) Compound
EP2443115A4 (en) COMPOUNDS
GB0922003D0 (en) Compound
GB0922714D0 (en) Compound
GB0916603D0 (en) Compound
GB0917460D0 (en) Compound
GB0910692D0 (en) Compound
GB0901976D0 (en) Compound
GB0906821D0 (en) Compound